News Sentiment

TGTX sentiment intelligence

TG Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 57.12 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+7.1% over one week, +15.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Law firm investigates TG Therapeutics officers for possible self-dealing harming shareholders

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 7.1% Price confirming higher
Trend fit Trend active 15.3% over four weeks
Fair value 114.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 30
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 17
TradingView 9
simplywall.st 5
Simply Wall Street 3
The Globe and Mail 3
Stocktwits 2
Insider Monkey 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 18
Analyst action 5
Balance sheet 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Pluang Direct company coverage

Law firm investigates TG Therapeutics officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating whether officers and directors of TG Therapeutics, Inc. (TGTX) breached their fiduciary duties through potential self-dealing. This investigation could result in damages for shareholders and corporate governance reforms for the company. Long-term

Tone
Negative 19/100
Event
Regulatory and legal
Published
17 Jul 2026 02:11
Source
Pluang
Simply Wall Street Direct company coverage

Did BRIUMVI’s Phase 2 Schizophrenia Trial Just Shift TG Therapeutics' (TGTX) Investment Narrative?

TG Therapeutics (TGTX) has initiated a Phase 2 trial for its drug BRIUMVI in treatment-resistant schizophrenia, expanding its potential use beyond multiple sclerosis. While this broadens the company's therapeutic footprint, the article suggests it doesn't significantly alter TG's

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 19:41
Source
Simply Wall Street
The Globe and Mail Direct company coverage

Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX)

Analysts have provided conflicting ratings for Biogen (BIIB) and TG Therapeutics (TGTX) within the Healthcare sector. Argus Research maintained a Hold rating on Biogen with an 11.3% upside price target, while Jefferies reaffirmed a Buy rating for TG Therapeutics, despite a minor

Tone
Neutral 50/100
Event
Analyst action
Published
16 Jul 2026 12:11
Source
The Globe and Mail
Stocktwits Direct company coverage

TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch

TG Therapeutics (TGTX) shares rose after Bank of America analyst Alec Stranahan increased his price target to $20 from $17, despite maintaining an 'Underperform' rating. This comes as the company initiated a mid-stage study for its key drug, Briumvi, in patients with treatment-re

Tone
Positive 65/100
Event
Analyst action
Published
16 Jul 2026 11:13
Source
Stocktwits
The Globe and Mail Direct company coverage

TG Therapeutics (TGTX) Gets a Buy from H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on TG Therapeutics (TGTX) with a price target of $77.00. The company reported strong quarterly revenues of $204.92 million and a net profit of $19.78 million for the quarter ending March 31, significantly up from the pr

Tone
Positive 72/100
Event
Analyst action
Published
14 Jul 2026 23:44
Source
The Globe and Mail
Sahm Direct company coverage

Is TG Therapeutics (TGTX) Fully Valued Following Its New Schizophrenia Trial Launch?

TG Therapeutics (TGTX) has garnered attention after initiating a Phase 2 trial for BRIUMVI in treatment-resistant schizophrenia, expanding beyond multiple sclerosis. Despite a significant share price increase of over 90% year-to-date, analysts estimate the stock is currently over

Tone
Negative 38/100
Event
Market update
Published
12 Jul 2026 23:41
Source
Sahm
TradingView Direct company coverage

ETFs Investing in TG Therapeutics, Inc. Stocks

This article lists various ETFs that invest in TG Therapeutics, Inc. (1TGTX) stocks, providing data such as market value, weight, issuer, management style, expense ratio, AUM, price, change percentage, and 3-year NAV total return. The ETFs cover a range of investment strategies,

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 10:09
Source
TradingView
Insider Monkey Direct company coverage

TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial

TG Therapeutics (NASDAQ:TGTX) has initiated a Phase 2 clinical trial for Briumvi, evaluating its efficacy and safety in adults with treatment-resistant schizophrenia. This follows recent positive Phase 1 data for Briumvi in myasthenia gravis and an increase in Jefferies' price ta

Tone
Positive 70/100
Event
Market update
Published
09 Jul 2026 06:40
Source
Insider Monkey
The Globe and Mail Direct company coverage

TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia

TG Therapeutics (TGTX) has initiated a phase II study for Briumvi (ublituximab-xiiy) to treat adult patients with treatment-resistant schizophrenia, aiming to assess its safety and efficacy in B-cell depletion. Briumvi, already approved for relapsing multiple sclerosis, generated

Tone
Positive 89/100
Event
Market update
Published
08 Jul 2026 10:09
Source
The Globe and Mail
Insider Monkey Direct company coverage

5 Best Performing American Stocks in June 2026

This article lists the top 5 performing American stocks in June 2026, extracted from a longer list of 10. It details the performance and recent activities of TG Therapeutics, Inc. (NASDAQ:TGTX), including clinical trial initiations and analyst price target updates. The article al

Tone
Positive 71/100
Event
Analyst action
Published
07 Jul 2026 20:50
Source
Insider Monkey
Simply Wall Street Direct company coverage

Is BRIUMVI’s Trial in Treatment-Resistant Schizophrenia Altering The Investment Case For TG Therapeutics (TGTX)?

TG Therapeutics has initiated a Phase 2 trial for BRIUMVI in treatment-resistant schizophrenia, aiming to expand its B-cell-targeting drug beyond multiple sclerosis into a new psychiatric indication. While this scientifically interesting move broadens BRIUMVI's potential, the art

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 14:11
Source
Simply Wall Street
TradingView Direct company coverage

TG Therapeutics, Inc. Stock 12‑Month Price Target Raised to $52.14, Implies 6% Downside

Analysts have raised the average 12-month price target for TG Therapeutics, Inc. (TGTX) stock to $52.14, up from $51.71, with individual forecasts ranging from $20 to $83 per share. Despite this increase, the updated target suggests a potential 6% downside based on the July 6 clo

Tone
Negative 39/100
Event
Analyst action
Published
07 Jul 2026 13:11
Source
TradingView
GlobeNewswire Direct company coverage

TG Therapeutics Announces Initiation of Phase 2 Trial

TG Therapeutics has initiated a Phase 2 clinical trial to evaluate BRIUMVI (ublituximab-xiiy) in approximately 60 adults with treatment-resistant schizophrenia. The study aims to determine if B-cell depletion, a mechanism of action for BRIUMVI, can improve symptoms in patients wh

Tone
Positive 73/100
Event
Market update
Published
06 Jul 2026 21:11
Source
GlobeNewswire
grafa.com Direct company coverage

TG Therapeutics begins schizophrenia Phase 2 trial

TG Therapeutics (NASDAQ:TGTX) has initiated a Phase 2, open-label, multicenter study of BRIUMVI (ublituximab-xiiy) for treatment-resistant schizophrenia. The trial involves approximately 60 adult participants who will receive BRIUMVI alongside standard antipsychotic therapy. The

Tone
Positive 65/100
Event
Market update
Published
06 Jul 2026 13:38
Source
grafa.com
Stock Titan Direct company coverage

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

TG Therapeutics (NASDAQ:TGTX) has initiated a Phase 2, open-label trial to assess the efficacy and safety of BRIUMVI (ublituximab-xiiy) in approximately 60 adults with treatment-resistant schizophrenia. The study will combine intravenous BRIUMVI with standard antipsychotic therap

Tone
Positive 67/100
Event
Market update
Published
06 Jul 2026 11:42
Source
Stock Titan
Finviz Direct company coverage

TGTX - TG Therapeutics Inc Dividends

This article provides a detailed financial overview of TG Therapeutics Inc (TGTX), including its latest stock performance, market capitalization, income, sales, and various financial ratios. It highlights key metrics such as P/E, EPS, sales growth, and insider/institutional owner

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 20:09
Source
Finviz
Market source Direct company coverage

Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?

TG Therapeutics' drug Briumvi has shown strong sales growth, with Q1 2026 sales reaching $201.3 million, and Q2 net sales in the U.S. projected at $220 million. The company faces stiff competition in the multiple sclerosis market from established players like Roche and Novartis,

Tone
Positive 70/100
Event
Market update
Published
03 Jul 2026 08:31
Source
Market source
TradingView Direct company coverage

Price to sales forward of TG Therapeutics, Inc. – NASDAQ:TGTX

This article provides the "Price to sales forward" metric for TG Therapeutics, Inc. (NASDAQ: TGTX). It lists the period, value, change, and change percentage for this financial indicator. The content is presented as a singular data point within a financial overview for the compan

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 23:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of TG Therapeutics, Inc. – MIL:1TGTX

This article displays the "Price to earnings forward" value for TG Therapeutics, Inc. (MIL:1TGTX). It indicates that the market is currently closed with no trades. The article also provides a list of data providers and copyright notices.

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 20:39
Source
TradingView
Moomoo Direct company coverage

Does TG Therapeutics (NASDAQ:TGTX) Deserve A Spot On Your Watchlist?

This article evaluates TG Therapeutics' stock (NASDAQ: TGTX) as a potential investment by analyzing its financial health, growth prospects, and valuation. It highlights the company's strong revenue growth, positive shareholder returns over the past year, and relatively low debt.

Tone
Positive 67/100
Event
Earnings
Published
29 Jun 2026 14:10
Source
Moomoo